Document is current
Any future updates will be listed below
-
Authors
Estravís, Miguel https://orcid.org/0000-0001-9788-4540
García-Sánchez, Asunción https://orcid.org/0000-0002-9655-4918
Martin, Maria J. https://orcid.org/0000-0002-3687-2789
Pérez-Pazos, Jacqueline https://orcid.org/0000-0002-2023-781X
Isidoro-García, María https://orcid.org/0000-0002-9013-9422
Dávila, Ignacio https://orcid.org/0000-0001-8485-5513
Sanz, Catalina https://orcid.org/0000-0003-2974-0873
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI17/00818)
Instituto de Salud Carlos III (PI20/00268)
Instituto de Salud Carlos III (RD16/0006/0019)
Consejería de Educación, Junta de Castilla y León (IES161P20)
Gerencia Regional de Salud, Junta de Castilla y León (GRS2156/A/20)
Universidad de Salamanca
- License Information
-
More Information
Article History
Received: 13 January 2022
Accepted: 29 August 2022
First Online: 12 September 2022
Declarations
:
: I.D. reports personal fees from Novartis, Sanofi, GSK, Astra-Zeneca, LETI, and Teva, and grant and personal fees from Thermo Fisher outside the submitted work. The rest of the authors declare no conflict of interest.
: The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
